A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression

Q: What does this research mean for the field?

BPL-003 (5-methoxy-N,N-dimethyltryptamine) leads to a rapid and sustained reduction in depression symptoms in patients with treatment-resistant depression (TRD). Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

Claire T. Roberts; Mathieu Seynaeve; Anna O. Ermakova; Fiona Dunbar; Hattie Wells; Adeep Puri; Catherine Bird; James Rucker

doi:10.1177/02698811261420087

February 27, 2026Journal of PsychopharmacologyOpen Access

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the safety and effectiveness of BPL-003 in patients with treatment-resistant depression.
Conducted as an uncontrolled, open-label phase 2 trial
Administered BPL-003 intranasally to participants
Monitored changes in depression symptoms using the MADRS scale over 12 weeks
Confirmed safety profile of BPL-003 in treatment-resistant depression population
Observed rapid and sustained reduction in MADRS scores
Findings suggest potential benefits, warranting larger controlled trials

Implication

Phase 2 study shows rapid reduction in depression symptoms in treatment-resistant depression, suggesting further research is needed.

Abstract

Results confirmed the safety profile of BPL-003 in a TRD population. A rapid and sustained reduction in MADRS score was observed over 12 weeks, suggesting BPL-003 could be beneficial in TRD, warranting investigation in larger controlled trials.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Roberts et al. (2026) studied this question.

synapsesocial.com/papers/69a52e45f1e85e5c73bf1c4b https://doi.org/10.1177/02698811261420087

View Full Paper

Ask AI

Bookmark

Share

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression

Key Points

Implication

Abstract

Discussion

Cite This Study

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading